Merck releases new data on effectiveness of Cognigram
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cogstate
- Fully Underwritten Non-Renounceable Rights Issue / Placement
- Business Update and First Half Financial Guidance
- 30 Sep 2013 Business Update and Appendix 4C
- Precision Recruitment chosen for phase III Alzheimers study
- Contracts signed since 1 July 2014 hit $9 million
Later from Cogstate
- CogState partners with Merck Canada
- CogState Signs Contract For Phase 2 Schizophrenia Study
- CogState signs sales contract for large phase 2 study
- CogState signs sales contract for phase 2 study
- CogState signs sales contract for phase 3 study
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate